Zimmer Biomet Holdings, Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Health Care Equipment and Supplies | Market Cap: ₹16.0K Cr
- U.S. - Zimmer Biomet raised its 2026 adjusted EPS guidance to $8.40 to $8.55, up from $8.30 to $8.45.
From Zimmer Biomet Holdings, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹82.82
Market Cap
₹16.0K Cr
P/E Ratio
21.9
Revenue Rank
Margin Rank
How does Zimmer Biomet Holdings, Inc. rank in Health Care Equipment and Supplies?
Compare Zimmer Biomet Holdings, Inc. against every Health Care Equipment and Supplies company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 4- →U.S. business grew 3.2% in Q1 2026; international grew 2.5%.
- →Overall organic constant currency revenue growth guidance for 2026 maintained at 1% to 3%.
- →Growth expected to be roughly consistent throughout 2026.
- →Paragon 28 acquisition to contribute ~100 basis points to reported sales growth in 2026.
- →Technology and data, bone cement, surgical business grew nearly 12% in Q1 driving growth.
- →Knee market: U.S. knees grew 2.2% with strong partial knee sales; hips grew 5% in the U.S.
- →International markets expected mid-single digit growth in second half of 2026.
- →Monogram robotic system launch anticipated in early 2027 expected to drive future growth.
- →Sales force transformation enhancing productivity and specialty focus to support growth.
- →Pricing erosion expected up to 100 basis points in 2026, consistent with guidance.
- →Free cash flow growth guidance raised to 9%-11% for 2026.
📈 Profitability & Margins
Rank 4- →Zimmer Biomet raised its 2026 adjusted EPS guidance to $8.40 to $8.55, up from $8.30 to $8.45.
- →Free cash flow growth guidance increased to 9% to 11%, from the previous 8% to 10%.
- →Operating margins for 2026 are expected to be slightly down, better than previously anticipated, with a modest decline of less than 50 basis points from 2025, despite investments and acquisition dilution.
- →Q2 2026 operating margins are expected to be down roughly 200 basis points from Q2 2025; Q3 expected to improve sequentially by about 50 basis points.
- →Pricing pressures anticipated with a full-year assumption of up to 100 basis points of price erosion.
- →The company remains confident in the direction given strong Q1 results, ongoing go-to-market transformations, and robust innovation pipeline, with updates expected in the August call.
🏗️ Capital Expenditure Plans
Yes- →Zimmer Biomet is investing heavily in innovation and go-to-market transformation, including technology launches like Monogram (expected early 2027) and expansion of the sales force with over 200 new reps specifically for Monogram.
- →The company is expanding its manufacturing footprint into lower-cost geographies to improve operational efficiency and margins.
- →There is a sizable investment focus on building clinical evidence, economic strategy, and new customer targeting strategies to drive adoption of new products.
- →Zimmer Biomet committed as the exclusive orthopedic investor in the Mobility Revolution Fund, a musculoskeletal venture capital fund focusing on breakthrough technologies such as AI, data applications, and cartilage repair.
- →Hiring Dr. Jonathan [indiscernible] as Chief Science Technology and Medical Affairs Officer to lead strategy and innovation around AI-enabled robotics, software, smart implants, and connected technologies.
- →Investments support future-proofing the company and building a robust technology portfolio, including connected and robotic solutions (Monogram, ROSA, TMINI).
💰 Fundraising & Capital Structure
No information- →There is no mention of any current or planned fundraising through new debt or equity in the provided transcript.
- →The company continues to assume up to $750 million of share repurchases remain unchanged, indicating share buybacks rather than issuance.
- →Interest expense, tax rate, and share count guidance remain stable, suggesting no new significant debt issuance planned.
- →Focus appears to be on operational excellence, innovation, and go-to-market transformation funded internally.
- →No discussion of new financing rounds, equity offerings, or debt raises was made during the Q&A or remarks.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Health Care Equipment and Supplies this season
- Insulet Corporation (Q2 FY26)
Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24
- Globus Medical, Inc. (Q2 FY26)
Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.
- Align Technology, Inc. (Q2 FY26)
Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap
- Solventum Corporation (Q2 FY26)
Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag
Frequently Asked Questions
What were Zimmer Biomet Holdings, Inc. Q2 FY26 results?
- U.S. - Zimmer Biomet raised its 2026 adjusted EPS guidance to $8.40 to $8.55, up from $8.30 to $8.45.
What is Zimmer Biomet Holdings, Inc. share price analysis?
Zimmer Biomet Holdings, Inc. currently shows a neutral. The stock trades at a P/E of 21.9 with a market cap of $16,023. Investors should review the full earnings analysis for detailed insights.
Is Zimmer Biomet Holdings, Inc. planning capital expenditure?
- Zimmer Biomet is investing heavily in innovation and go-to-market transformation, including technology launches like Monogram (expected early 2027) and expansion of the sales force with over 200 new reps specifically for Monogram. - The company is expanding its manufacturing footprint into lower-cost geographies to improve operational efficiency and margins. - There is a sizable investment focus on building clinical evidence, economic strategy, and new customer targeting strategies to drive adoption of new products. - Zimmer Biomet committed as the exclusive orthopedic investor in the Mobility Revolution Fund, a musculoskeletal venture capital fund focusing on breakthrough technologies such as AI, data applications, and cartilage repair. - Hiring Dr.
Keep Zimmer Biomet Holdings, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.